Annovis Bio’s (ANVS) Buy Rating Reiterated at HC Wainwright

Annovis Bio (NYSE:ANVS)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued on Tuesday, Benzinga reports. They currently have a $30.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 311.52% from the company’s previous close.

A number of other research analysts have also commented on ANVS. Brookline Capital Management lowered Annovis Bio from a “buy” rating to a “hold” rating and set a $9.00 price target for the company. in a research report on Wednesday, February 28th. Canaccord Genuity Group reduced their target price on Annovis Bio from $36.00 to $26.00 and set a “buy” rating on the stock in a research note on Tuesday.

Annovis Bio Stock Down 59.5 %

NYSE:ANVS opened at $7.29 on Tuesday. The firm has a market capitalization of $80.26 million, a P/E ratio of -1.17 and a beta of 1.59. The company has a fifty day moving average of $10.58 and a 200 day moving average of $10.30. Annovis Bio has a 52 week low of $5.23 and a 52 week high of $22.49.

Annovis Bio (NYSE:ANVS) last released its quarterly earnings data on Friday, March 29th. The company reported ($1.09) earnings per share (EPS) for the quarter. As a group, analysts anticipate that Annovis Bio will post -3.35 EPS for the current year.

Institutional Trading of Annovis Bio

Several large investors have recently bought and sold shares of ANVS. Adage Capital Partners GP L.L.C. purchased a new stake in Annovis Bio in the third quarter worth $2,847,000. Private Trust Co. NA purchased a new stake in shares of Annovis Bio in the 4th quarter worth about $56,000. Greenwich Wealth Management LLC purchased a new stake in shares of Annovis Bio in the 4th quarter worth about $192,000. Finally, Wealthspire Advisors LLC increased its stake in shares of Annovis Bio by 9.9% in the 4th quarter. Wealthspire Advisors LLC now owns 10,990 shares of the company’s stock worth $206,000 after acquiring an additional 990 shares in the last quarter. 15.83% of the stock is owned by institutional investors.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.